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Abstract
Introduction: Infection promotes coagulation via a large number of molecular and cellular mechanisms,
and this procoagulant activity has boosted basic and clinical research using anticoagulant molecules as
therapeutic tools in sepsis. Heparin, which is a naturally occurring proteoglycan that acts by reducing
thrombin generation and fibrin formation, has not been rigorously tested in a randomized clinical trial.
Methods:  Randomized, double-masked, placebo-controlled, single-center clinical trial. Patients are
recruited through the emergency room at Hospital Universitario San Vicente de Paul. This is a 650-bed
University Hospital in Medellín, Colombia and is a referral center for a region with approximately 3 million
habitants. The recruitment process started on July 2005 and will finish on June 2007. Patients aged 18 years
or older, males or females, hospitalized with clinically or microbiological confirmed sepsis, have been
included. The interventions are unfractioned heparin in low dose continuous infusion (500 units per hour
for 7 days) or placebo, additionally to the standard of care for sepsis patients in Colombia.
Results: Our primary aims are to estimate the effects of heparin on hospital length of stay and change
from baseline Multiple Organ Dysfunction (MOD) score. Secondary objectives are to estimate the effects
of heparin on 28-day all-cause mortality, and to estimate the possible effect modification on 28-day all-
cause mortality, in subgroups defined by source and site of infection, and baseline values of APACHE II
score, MOD score and D-dimer.
Conclusion:  The available literature in animal and human research, and the understanding of the
molecular biology regarding inflammation and coagulation, supports a randomized clinical trial for the use
of heparin in sepsis. Our study will provide appropriate power to detect differences in valid surrogate
outcomes, and it will explore important preliminary data for efficacy regarding the clinical end-point of
mortality.
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Background
Sepsis is considered a leading cause of death worldwide
with approximately 18 millions cases annually and a mor-
tality rate of almost 30% [1]. In Colombia, the country in
which this study will be conducted, there are no national
estimates of sepsis incidence. However, our previous
investigations have provided some relevant data: in a 650
bed University-based Hospital, bacteremia and/or sepsis
were considered a main diagnosis in 7 out of 100 admis-
sions to the emergency room; and blood cultures were
requested in 2 out of 10 inpatients at some time during
their hospitalization [2,3]. The overall 28-day sepsis mor-
tality rate ranged from 25% to 40%, depending on the
growth of microorganisms in blood cultures [2-4].
In the last two decades the accepted standard treatment
for sepsis has resulted in only a slight decrease in mortal-
ity, and that decrease has been overshadowed by an
almost 300% increase in incidence [5]. Unfortunately, the
search for efficacious therapeutic approaches has largely
failed and only a few of the recent interventions -as early
goal directed therapy, activated protein C and low dose
steroids- have shown success in improving survival [6,7].
However, these interventions were tested only in patients
with severe sepsis and septic shock and although these
groups exhibit the highest mortality, they may represent
less than 50% of the total affected population [8,9]. Fur-
thermore, these interventions necessitate special devices,
tests or drugs that might be unavailable or simply unaf-
fordable in resource-limited settings.
Several investigators have documented the close relation-
ship between infection, inflammation and coagulation in
sepsis [10-12]; and although clinically overt disseminated
intravascular coagulation (DIC) may occur in only 30%–
50% of septic patients, the activation of coagulation cas-
cade is an early and common response to the infectious
challenge [13-15]. In turn, most of the molecules involved
in the pro-coagulant state that characterizes sepsis are also
powerful generators or amplifiers of the inflammatory
response [16,17]. The rationale behind anticoagulant
treatments is that certain factors -activated protein C
(APC), Antithrombin (AT) and Tissue Factor Pathway
Inhibitor (TFPI) – are depleted, and the use of recom-
binant technology may replenish them. In contrast,
heparin does not simply replenish what sepsis patients
have depleted, it binds to and activates AT. As a conse-
quence of this activation, heparin dramatically reduces
thrombin generation and fibrin formation. Rather than
artificially providing a component in the regulatory sys-
tem, heparin takes advantage of the one existing molecule
in its natural environment to increase its activity a thou-
sand-fold [18].
Animal and human models have suggested that heparin,
in addition to successfully inhibiting the coagulation cas-
cade in sepsis, may also modulate a wide array of
responses to infection [19-23]. Furthermore, the three
clinical trials for recombinant anticoagulants allowed the
use of prophylactic treatment for venous thrombosis with
a dose of heparin of up to 10,000 or 15,000 units subcu-
taneously per day [24-26]. Although heparin was not
given based on a random allocation, when those who did
receive heparin were compared to those who did not in
the placebo arms of the clinical trials, all three studies
showed a higher mortality in the subgroups that did not
receive heparin. Despite the obvious limitations of post-
randomization comparisons, a constant result in three
different study populations with variable entry criteria,
along with the natural heterogeneity of the illness,
strongly fosters the hypothesis that heparin might reduce,
beyond its known anticoagulant and antithrombotic
properties, the overall mortality for sepsis.
As noted in a recent editorial in JAMA [27], heparin is the
most widely available, least expensive, and most fre-
quently used anticoagulant; and despite the common rec-
ommendation of continuous infusion of low doses (300–
500 units/hour) in the treatment of DIC [13,28], its
potential and attractive usefulness as therapy for the treat-
ment of sepsis has not been rigorously tested in a rand-
omized clinical trial. Therefore, we are conducting a
clinical trial for testing low dose continuous infusion of
unfractioned heparin (500 units/hour for 7 days) as com-
plementary treatment for septic patients.
Our primary aims are to estimate the effects of heparin on
hospital length of stay and change from baseline Multiple
Organ Dysfunction (MOD) score [29]. Secondary objec-
tives are to estimate the effects of heparin on 28-day all-
cause mortality, and to estimate the possible effect modi-
fication on 28-day all-cause mortality, in subgroups
defined by source and site of infection, and baseline val-
ues of APACHE II score, MOD score and D-dimer.
Materials and methods
Study design
Randomized, double-masked, placebo-controlled, single-
center clinical trial.
Population
An ideal therapy should be viable for septic patients at the
earliest stage in their clinical course once the infectious
process is suspected or confirmed, and not only at the
point of admission to intensive care as has been the case
for virtually all previous sepsis trials. Although the defini-
tions for severe sepsis and septic shock have been rela-
tively easy, the identification of that "less ill" population
has been really hard to meet. In fact, currently we are lack-Trials 2006, 7:19 http://www.trialsjournal.com/content/7/1/19
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ing a standard definition for sepsis. We have shown [30]
that in the setting of the proposed study, the classical sys-
temic inflammatory response syndrome (SIRS) definition
was not inclusive enough to identify the full spectrum of
patients, since its sensitivity was less than 70% for a
cohort with a median length of stay of 11 days and an
overall hospital mortality of 21%. Thus, we are proposing
a set of inclusion criteria that may be useful to include the
wide spectrum of the syndrome. In addition to fulfilling
the operational criteria for inclusion, we are restricting our
population to the patients with a clinical picture as severe
enough to require inpatient treatment.
Patients will be recruited, between July 2005 and June
2007, through the emergency room at Hospital Universi-
tario San Vicente de Paul. This is a 650-bed University
Hospital in Medellín, Colombia and is a referral center for
a region with approximately 3 million habitants. Patients
aged 18 years or older, males or females, hospitalized with
a suspected or confirmed infection, unexplained fever,
unexplained altered mental status or unexplained arterial
hypotension (systolic blood pressure < 90 mm Hg or a
decrease > 40 mm Hg) will be considered potentially eli-
gible for the trial.
Inclusion criteria (table 1)
- Patients must have an infection defined by clinical and/
or microbiological criteria in accordance with modified
CDC definitions for nosocomial infections [31].
- Patients must present with one or more of the general
variables AND one or more of the inflammatory variables,
within 24 hours before admission to the study. These var-
iables should not be attributable to an underlying disease
other than infection or due to the effects of concomitant
therapy.
Exclusion criteria (table 2)
- Pregnant or breastfeeding.
- Platelet count < 60,000/mm3.
- Increased risk for bleeding
- Patients with a known hypercoagulable conditions
- Patients taking or requiring anticoagulant medications
- Patients with known esophageal varices, chronic jaun-
dice, cirrhosis, or chronic ascites.
- Presence of an advance directive to withhold life-sustain-
ing treatment
- Patients not expected to survive 28 days given their pre-
existing, uncorrectable medical condition.
- Patients with chronic renal failure on either hemodialy-
sis or peritoneal dialysis.
- HIV positive patients with most recent CD4 count < 200/
mm3.
- Patients who have undergone bone marrow, liver, lung,
kidney or pancreas transplantation.
- Inability or unwillingness of patients or legal represent-
ative to give written informed consent.
Randomization and following procedures
The treatment assignment ratio is 1:1, fixed throughout
the study. The allocation to heparin or placebo is defined
by randomly permuted blocks of size 2, 4 and 6 generated
by a random number generator (ralloc program, Stata co.
8.2, College Station, TX, USA). Complete treatments (four
ampoules for each patient, marked with the same sequen-
tial number corresponding to the randomization scheme)
are available in the emergency room's pharmacy center.
The placebo is packed identically to the heparin sodium
injection, and has the same color and volume as the
heparin. Therefore, procedures for administration (i.e.
loading dose and continuous infusion) are identical. Out-
come measures are documented by medical research
assistants masked to both the subject's intervention group
assignment and the activated partial thromboplastin time
(aPTT) values corresponding to specific days of the inter-
vention period.
Methods for dealing with potential adverse events
General treatment for patients is left up to the medical
team in charge of each patient, according to clinical prac-
tice guidelines for infectious diseases and critical care
available at the institution.
Basic considerations for dealing with potential adverse
events are:
- Infusion should be suspended indefinitely if there are
new signs or symptoms of hemorrhage such as bleeding
from gums, nosebleeds, extensive bruising, evidence of
purplish skin areas or gastrointestinal bleeding.
- Infusion should be suspended indefinitely if there is an
otherwise unexplained drop of 50% or greater in platelet
count, or an absolute platelet count below 30,000 cells
per mm3 any time during the study.
- Infusion should be interrupted 2 hours before any per-
cutaneous procedure or major surgery, and should onlyTrials 2006, 7:19 http://www.trialsjournal.com/content/7/1/19
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be resumed 1 hour after a percutaneous procedure or 12
hours after major surgery. In presence of bleeding compli-
cations with any of these procedures, infusion can only be
resumed after normal results in coagulation tests, and no
less than 24 hours after the procedure
- Infusion should be interrupted indefinitely if aPTT test is
prolonged more than 60 seconds at any time during the
infusion period.
Sample size
Length of stay may be considered a time to event end-
point, with patient discharge alive as the outcome. Those
who die during the hospital stay will be considered as
competing risks for this analysis because they are not cen-
sored observations. With a median length of stay of 11
days, a type I error of 0.05 and a type II error of 0.2, the
estimated number of patients required to detect a relative
hazard of being discharged alive of 1.3 is 231 [32]. This
Table 1: Inclusion criteria – HETRASE study
Modified CDC definitions for infection General variables Inflammatory variables
1) Pneumonia 1) Temperature (oral or axillary) > 38°C or < 
36°C
1) WBC > 12,000 µL-1 or < 4,000 µL-1 or with 
> 10% immature forms
2) Bloodstream infection 2) Heart rate > 90 beats/min 2) Plasma C-reactive protein > 5 mg/dL.
3) Clinical sepsis 3) Respiratory rate > 20 breaths/min
4) Symptomatic urinary tract infection and 
other infections of urinary tract
4) Altered mental status determined by 
Glasgow Coma Scale < 15
5) Intra-abdominal infections 5) Systolic blood pressure < 90 mm Hg or a 
decrease > 40 mm Hg
6) Skin infections
7) Soft tissue infections
8) Superficial and deep surgical site infections
9) Joint or bursa infections
Table 2: Exclusion criteria – HETRASE study
- Pregnant or breastfeeding.
- Platelet count < 60,000/mm3.
- Increased risk for bleeding:
a) Any patient who has undergone major surgery, defined as surgery that required general or spinal anesthesia, performed within the 12-hour 
period immediately preceding admission to the hospital; any postoperative patient who demonstrates evidence of active bleeding; or any patient 
with planned or anticipated major surgery during the first 12 hours after admission to the hospital.
b) History of: severe head trauma that required hospitalization, intracranial surgery, or stroke within 3 months of study entry; or any history of 
intracerebral arteriovenous malformation, cerebral aneurysm, or central nervous system mass lesion.
c) History of congenital bleeding diatheses, such as hemophilia.
d) Gastrointestinal bleeding within 6 weeks of study entry that required medical intervention unless definitive surgery has been performed.
e) Trauma patients at increased risk of bleeding, for example: flail chest; significant contusion to lung, liver, or spleen; retroperitoneal bleed; pelvic 
fracture; or compartment syndrome.
- Patients with a known hypercoagulable condition including activated Protein C resistance; a hereditary deficiency of Protein C, Protein S, or 
antithrombin; presence of anticardiolipin antibody, antiphospholipid syndrome, lupus anticoagulant or homocysteinemia; or patients with a recently 
documented (within 3 months of study entry) or highly suspected deep venous thrombosis or pulmonary embolism.
- Patients taking or requiring the following medications:
a) Therapeutic heparin, defined as UFH dosed to treat an active thrombotic or embolic event within the 12 hours prior to study entry or LMWH 
used at any dose higher or more frequent than the recommended dose on the product label for prophylaxis within the 12 hours prior to study 
entry.
b) Warfarin, if used within 7 days of study entry.
c) Thrombolytic treatment within 3 days of study entry (for example, streptokinase, rtPA, and urokinase).
d) Glycoprotein IIb/IIIa antagonists within 7 days of study entry.
- Patients with known esophageal varices, chronic jaundice, cirrhosis, or chronic ascites.
- Presence of an advance directive to withhold life-sustaining treatment
- Patients not expected to survive 28 days given their preexisting, uncorrectable medical condition. This criterion includes patients with, or 
suspected to have, poorly controlled neoplasms or other end-stage processes, such as end-stage cardiac disease, prior cardiac arrest, end-stage 
lung disease, or end-stage liver disease.
- Patients with chronic renal failure on either hemodialysis or peritoneal dialysis.
- HIV positive patients with most recent CD4 count < 200/mm3.
- Patients who have undergone bone marrow, liver, lung, kidney or pancreas transplantation.
- Inability or unwillingness of patients or legal representative to give written informed consent.Trials 2006, 7:19 http://www.trialsjournal.com/content/7/1/19
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number of events may be achieved with a total sample
size of 310 patients, assuming an overall hospital mortal-
ity of 25%.
MOD score data correspond to the case of longitudinal
data with correlated measurements, and as such require
special considerations for calculation of power and sam-
ple size [33]. The table 3 shows different estimates of
power under different assumptions of correlation among
repeated observations (ρ) and differences in rate of
change (∆) with a fixed sample size of 310 participants.
This sample size also will have an 80% power to detect a
50% relative reduction in the secondary outcome of over-
all 28-day mortality.
Interim monitoring
An independent Data and Safety Monitoring Board
(DSMB) comprising three members with expertise in sta-
tistics, epidemiology and critical care practice are respon-
sible for the interim monitoring process. The statistician
in the data-coordinating center is the only person with
access to the blind and the full data and he provides the
required information, both overall for the interim quality
assurance and specific by treatment group (efficacy and
safety) exclusively for the DSMB.
The first interim was conducted when the first 103 study
participants completed their 28-day vital status evaluation
-approximately 9 months after study recruitment began.
The second interim analysis will be conducted when 206
patients have been enrolled, approximately 16 months
after the study initiation. Stopping guidelines for efficacy
monitoring were determined according to the modified
O'Brien-Fleming procedure [34,35]. With this procedure,
the values for statistical significance will be 0.0006 and
0.0151 in the first (α1) and second (α2) interim analyses,
respectively, for a final significance (α) of 0.0471.
Analysis plan
Overall study efficacy will be established using the inten-
tion-to-treat principle, in which patients are analyzed in
the treatment group to which they are assigned at rand-
omization. Length of stay may be considered a time to
event time end-point with discharge as the outcome. The
graphical presentation of these survival distributions for
heparin and placebo groups will be estimated using the
Kaplan-Meier method, and the test statistic for compari-
son between these two survival distributions will be based
on the Log-rank test [32].
MOD score data correspond to the case of longitudinal
data with correlated measurements, and as such require
special statistical methods to account for the correlation
among observations. To analyze this kind of clustered
data, it is necessary to model both the regression of Y (the
outcome measure) on x (the intervention) and the within-
cluster dependence in a unified manner with the applica-
tion of a random-effects model for longitudinal data [36].
For secondary outcomes, the comparisons will be pre-
sented as absolute and relative differences in 28-day mor-
tality rates with exact 95% confidence intervals. The
statistic to test this secondary null hypothesis will be the
Chi-square test. Although the expectation is that randomi-
zation assists in balancing known and unknown prognos-
tic factors, this assignment process is not a guarantee
against the possibility that estimates of treatment effect
will be modified by covariate imbalance. Accordingly, the
estimated relative risk of mortality for heparin vs. placebo
will be adjusted by the most important prognostic factors
(age, APACHE II score and MOD score at baseline), using
a multiple logistic regression model.
The natural heterogeneity of sepsis supports the impor-
tance of exploring the efficacy of the intervention among
different subgroups of patients, as defined by characteris-
tics of the illness. As hypothesis-generating analysis, the
following interaction terms will be incorporated into the
logistic model described before:
- Treatment * Source of infection (pneumonia vs. others)
- Treatment * Site of acquisition (community vs. hospital)
- Treatment * APACHE II score at baseline (continuous
variable)
- Treatment * MOD score at baseline (continuous varia-
ble)
- Treatment * D-dimer at baseline (continuous variable)
IRB approvals
The protocol and the informed consent document were
reviewed and approved by the ethics committee responsi-
ble for oversight the study (Medical Research Center, Uni-
versidad de Antioquia -U de A-, Medellín, Colombia), and
by the Committee on Human Research at Johns Hopkins
Bloomberg School of Public Health (CHR#:
H.34.04.04.27.B1)
Table 3: Power estimates for differences (∆) in MOD score with a 
fixed sample size of 155 patients per group and selected values of 
correlation (ρ)
ρ ∆ 3 points 2 points 1 point
0.8 100% 99% 98%
0.5 100% 98% 97%Trials 2006, 7:19 http://www.trialsjournal.com/content/7/1/19
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Discussion
Sepsis is a leading cause of morbidity and mortality
worldwide, and it is reasonable to assume that the magni-
tude of the problem is accentuated (i.e., higher costs and
burden of disease) in developing countries. Thus, consid-
ering the problem of resource-limited settings, ideal char-
acteristics of therapies that complement standard care
might include the following: efficacious, effective, simple
and inexpensive. Therapies should be void of adverse
events as much as possible, and should be widely availa-
ble [37]. Therefore, we will test the hypothesis that unfrac-
tioned heparin (low-dose continuous-infusion: 500
units/hour during 7 days) is efficacious as a complemen-
tary treatment in patients with signs indicative of sepsis.
This dose was selected based on the best risk/benefit ratio.
It has the ability to activate AT and reduce fibrin without
the potential risks of full anticoagulation. In addition, this
amount is equivalent to the dose widely used as prophy-
lactic treatment for patients considered at risk for venous
thrombosis (10,000 to 15,000 units subcutaneously per
day).
Several animal and preclinical studies have explored the
potential benefits of heparin in bacterial infections. Meyer
and coworkers hypothesized that heparin may increase
cardiac output and oxygenation [20]. Fourteen sheep
received continuous infusion of Escherichia coli endotoxin
over 24 hours. Seven animals received a fixed dose of
5,000 units of heparin every 4 hours immediately after
starting the endotoxin infusion and the other seven sheep
served as controls. The heparinized animals showed a tri-
phasic cardiovascular response, characterized by increase
in cardiac index and decrease in systemic vascular resist-
ance in the first two hours, followed by a return to approx-
imately baseline levels at four hours. In the last phase (8
to 24 hours), cardiac index increased and systemic vascu-
lar resistance decreased significantly, accompanied by a
marked improvement in oxygenation variables (arterial
oxygen tension and mixed venous oxygen saturation)
compared to the control group.
Schiffer et al compared hirudin, a specific and extremely
potent thrombin inhibitor, to heparin in terms of endo-
toxin-induced DIC and subsequent multiple organ failure
[38]. Twenty-two sheep were allocated to one of three
treatment groups: a) normal saline; b) continuous infu-
sion with conventional unfractioned bovine lung heparin;
and c) continuous infusion with recombinant hirudin.
After a 6-hour period of baseline evaluation, Escherichia
coli endotoxin was administered. Infusion of endotoxin
was lethal for all sheep allocated to the control and hiru-
din groups, whereas four of the seven animals receiving
the continuous heparin infusion survived to the end of
the study. In the control group, animals died between 6
and 44 hours of the start of endotoxin administration and
between 8 and 30 hours in the hirudin group. The three
deaths in the heparin group occurred between 48 and 56
hours following the start of endotoxin administration,
and the difference in survival rate as compared with the
two other treatment groups was statistically significant.
The most noteworthy finding in this study was the inabil-
ity of hirudin to protect animals from the development of
DIC, and to prevent multiple organ failure and subse-
quent death in a manner similar to that of heparin. The
authors offered several possible explanations of these
results: the time course of thrombin-antithrombin com-
plex production indicates that hirudin was less efficient
than heparin in preventing thrombin generation. Given
that hirudin acts directly on free thrombin, it is possible
that the amount of thrombin neutralized by hirudin is not
enough to slow its generation through the activated factor
X, and eventually, other co-factors such as V and VIII.
Additionally, the heparin-AT complex reduces the endo-
toxin-induced generation of plasminogen activator inhib-
itor type 1 (PAI-1), thus favoring a pro-fibrinolytic effect
not observed with hirudin [38]. Although the main action
of heparin results from the inactivation of clotting pro-
teases by AT, some inhibitory actions are independent of
coagulation. Instead, they seem related to a large-spec-
trum of nonspecific enzyme inhibition activity [16].
In 1983, Haneberg et al conducted the first controlled
clinical trial in humans to evaluate heparin, studying 26
infants and children with severe meningococcal sepsis
[39]. Eleven patients received intravenous heparin "as
early as possible following admission to hospital" and
continuously for two days. Fifteen children received only
the standard treatment. There were two deaths in each
group and the clinical course of the surviving patients did
not exhibit significant improvement. The study did not
include data regarding time before admission, clinical
severity, comorbidities, co-interventions or other poten-
tial important differences between groups.
Pernerstorfer et al [22] studied 30 healthy male volunteers
in three groups of 10 subjects. All 30 study subjects
received lipopolysaccharide (LPS) 2 ng/kg IV. Ten minutes
after LPS infusion, subjects in the heparin group received
80 IU/kg, followed by a continuous infusion at a rate of
18 IU/kg/hour for 6 hours, and subjects allocated to the
low molecular weight heparin (LMWH) group received
dalteparin 40 IU/kg followed by continuous infusion of
15 IU/kg/hour. Ten subjects served as controls. Activation
of coagulation, as a consequence of LPS infusion, caused
marked increases in plasma levels of prothrombin frag-
ment F1+2 (10-fold) and polymerized soluble fibrin (6-
fold) in the placebo group. LPS infusion also increased
subjects' D-dimer levels in the same group (5-fold). In
contrast, heparin infusion completely abolished F1+2 gen-Trials 2006, 7:19 http://www.trialsjournal.com/content/7/1/19
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eration and D-dimer production, whereas F1+2 and D-
dimer levels increased approximately 2-fold in the LMWH
group. In accordance with the primary role of tissue factor
(TF) on coagulation activation in sepsis, TF-positive
monocytes doubled after LPS infusion in the placebo
group. Interestingly, heparin completely blocked this LPS-
induced increase in TF-positive monocytes.
Working with the same study population described
above, Derhaschnig et al reported their findings on early
inflammatory responses [23]. Neutrophil and platelet
counts decreased by a maximum of 15% between 70 min-
utes and 112 minutes after LPS infusion and these
changes were not modified by any treatment. In contrast,
LPS-induced lymphocytopenia was significantly less pro-
nounced in the heparin group. In concordance with this
result, the expression of L-selectin, an adhesion molecule
with a pivotal role in lymphocyte homing, decreased by
32% in the placebo group after 6 hours but only by 5%
and 24% in the heparin and LMWH groups, respectively.
Tumor necrosis factor alfa (TNF-α) levels increased > 350-
fold in the LMWH and placebo groups, but only 150-fold
in the heparin group (p = 0.07). C-reactive protein levels
(CRP) were 4.5 mg/dL in the placebo group (range 2.8–
6.1), 3.9 mg/dL in the LMWH group (3.0–4.8) and 3.0
mg/dL (1.8–4.0) in the heparin group.
Boldt et al conducted a study to assess whether continu-
ous heparinization influenced plasma levels of circulating
adhesion molecules in intensive care patients [21].
Twenty-eight trauma patients and 28 patients who had
developed sepsis secondary to major abdominal surgery
were included in the study. Heparin was administered
intravenously (600 units/hour) to 14 patients in each
group -trauma and sepsis- approximately 24 hours after
arrival in the intensive care unit, with an equal number of
subjects serving as controls. The following adhesion mol-
ecules were measured daily: soluble endothelial leukocyte
adhesion molecule-1 (sELAM-1), vascular cell adhesion
molecule-1 (sVCAM-1), intercellular adhesion molecule-
1 (ICAM-1) and soluble granule membrane protein 140
(sGMP-140). There were no significant differences
between groups. There was no investigation of organ dys-
function or septic shock during the period of study, and
with the exception of platelet count and the Pao2/Fio2
index, no other relevant hematological, biochemical or
inflammatory parameters were followed.
In summary, experimental models of human endotox-
emia have demonstrated a wide range of ways in which
heparin may block the pro-coagulant activity that charac-
terizes sepsis. But the expression of a subsequent inhibi-
tion in the inflammatory pathways has not been as clearly
illustrated in human models as it has been in animal
models. On the other hand, in the clinical setting of sep-
sis, neither the anticoagulant effect nor the broad anti-
inflammatory and/or catalytic properties of heparin have
been appropriately evaluated. The measurements of organ
dysfunction over time and hospital length of stay may
accomplish this goal, as a first approach to determine the
potential efficacy of the drug.
Conclusion
The available literature in animal and human research,
and the understanding of the molecular biology regarding
inflammation and coagulation, supports a randomized
clinical trial for the use of heparin in sepsis. Our study will
provide appropriate power to detect differences in valid
surrogate outcomes, and it will explore important prelim-
inary data for efficacy regarding the clinical end-point of
mortality.
Key messages
- A pro-coagulant state is the hallmark in the inflamma-
tory response that characterizes sepsis.
- Some biological products with anticoagulant activity
have been tested in clinical trials, as complementary treat-
ment for septic patients.
- Several animal and pre-clinical studies have suggested
potential benefits for unfractioned heparin in bacterial
infections.
- A randomized clinical trial of heparin in sepsis is on
course, and it will provide important preliminary data for
efficacy and safety.
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